Sang-Woo Park
Director Ejecutivo en NKMAX CO., LTD. .
Fortuna: 794 962 $ al 30/04/2024
Perfil
Sang-Woo Park is the founder and currently holds the position of Chairman & Chief Executive Officer at NKMAX Co., Ltd.
(South Korea), which was founded in 2002.
He is also the founder and Director at NKGen Operating Biotech, Inc., which was founded in 2002.
Additionally, Mr. Park is the founder and Director at NKGen Biotech, Inc., which was founded in 2017.
In his current roles, Mr. Park is the Chief Executive Officer & Director at NKMAX Co., Ltd.
(South Korea) since 2002, Chief Executive Officer at ATGen Canada, Inc. since 2013, Chief Executive Officer at ATGen America, Inc. since 2014, Chief Executive Officer at Atgen H&D since 2016, Chief Executive Officer at coAsia Biotech Corp.
since 2016, Chief Executive Officer at Nkmax H&D Co. Ltd.
since 2016, Chief Executive Officer at Atgen Japan since 2017, and Chief Executive Officer at Nkmax Japan, Inc. since 2017.
Mr. Park's former position includes being the Chief Executive Officer & Director at J way Co., Ltd.Mr. Park completed his undergraduate degree at Korea University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
1.74% | 13/12/2023 | 397 378 ( 1.74% ) | 786 808 $ | 30/04/2024 |
NKMAX CO., LTD.
0.01% | 26/01/2024 | 5 418 ( 0.01% ) | 8 154 $ | 31/03/2024 |
Cargos activos de Sang-Woo Park
| Empresas | Cargo | Inicio |
|---|---|---|
| NKMAX CO., LTD. | Director Ejecutivo | 14/01/2002 |
| ATGen America, Inc. | Director Ejecutivo | 01/02/2014 |
| ATGen Canada, Inc. | Director Ejecutivo | 01/09/2013 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Director Ejecutivo | 01/01/2016 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Director Ejecutivo | 01/01/2002 |
| Nkmax H&D Co. Ltd. | Director Ejecutivo | 01/06/2016 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Director Ejecutivo | 01/04/2016 |
| Atgen Japan | Director Ejecutivo | 01/09/2017 |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Fundador | 01/01/2002 |
| ░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Antiguos cargos conocidos de Sang-Woo Park.
| Empresas | Cargo | Fin |
|---|---|---|
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░ | - |
Formación de Sang-Woo Park.
| Korea University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Empresas privadas | 9 |
|---|---|
| ATGen Canada, Inc. | |
| ATGen America, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Nkmax H&D Co. Ltd. | |
| Atgen Japan | |
NKGen Biotech, Inc.
NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
- Bolsa de valores
- Insiders
- Sang-Woo Park
